세계의 당뇨병성 신경병증 시장 보고서(2023년)

“Diabetic Neuropathy Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic neuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic neuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The diabetic neuropathy market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Disorder: Peripheral Neuropathy; Autonomic Neuropathy; Proximal Neuropathy; Focal Neuropathy

• 2) By Drug Class: Analgesics; Anti-Depressants; Anti-consulvants; Other Drug Classes

• 3) By Treatment: Drug Treatment; Radiotherapy; Physiotherapy; Other Treatments

• 4) By Distribution Channel: Online Distribution; Offline Distribution

• 5) By End-user: Hospitals; Specialty Clinics; Other End-users

• Companies Mentioned: Pfizer Inc.; Eli Lilly and Company; GSK PLC (GlaxoSmithKline PLC); Daiichi Sankyo Company Limited; Johnson & Johnson

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the diabetic neuropathy market are Pfizer Inc., Eli Lilly and Company, GSK PLC (GlaxoSmithKline PLC), Daiichi Sankyo Company Limited, Johnson & Johnson, Glenmark Pharmaceuticals Limited, Depomed Inc., Astellas Pharma Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc., Abbott Laboratories, Lupin Limited, Novartis AG, Boehringer Ingelheim, and Janssen Pharmaceuticals Inc.

The global diabetic neuropathy market is expected to grow from $4.52 billion in 2022 to $4.97 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diabetic neuropathy market is expected to reach $6.90 billion in 2027 at a CAGR of 8.5%.

The diabetic neuropathy market consists of sales of drugs such as anticonvulsants, pain medications, nerve growth factor inhibitors and other drugs that are used to treat the symptoms of nerve damage caused by diabetes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes. High blood sugar levels induce it, which can damage the blood vessels. It can harm various nerves in the body, including those in the feet, organs, and muscles.

North America was the largest region in the diabetic neuropathy market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thw diabetic neuropathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main disorders of diabetic neuropathy are peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. Peripheral neuropathy is a disorder that occurs when the peripheral nerves, which carry information to and from the brain and spinal cord to the rest of the body, are damaged. The various classes of drugs used for diabetic neuropathy are analgesics, anti-depressants, anti-convulsants, and others, that involve drug treatment, radiotherapy, physiotherapy, and others. These are provided through several distribution channels, such as online distribution and offline distribution, which are used in hospitals, specialty clinics and others.

The rising prevalence of diabetes is expected to boost the growth of the diabetic neuropathy market going forward. Diabetes is a persistent disorder where the body struggles to use and store glucose appropriately (a type of sugar). Diabetes occurs when the body either does not create enough insulin (a hormone that aids in blood sugar regulation) or does not use insulin effectively. Diabetic neuropathy is a type of nerve injury that can occur in diabetics with d ifferent forms of nerve damage causing different symptoms. For instance, in August 2022, according to the IDF Diabetes Atlas report published by the International Diabetes Federation, a Belgium-based global diabetes community and an umbrella organization of over 230 national diabetes associations, 6.7 million deaths were attributed to diabetes in the year 2021, which is equivalent to one death every five seconds. There are currently 537 million adults (aged 20-79) living with diabetes, or 1 in 10 people. It is estimated that this number will increase to 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic neuropathy market.

Technological advancements have emerged as a key trend gaining popularity in the diabetic neuropathy market. Major companies operating in the diabetic neuropathy market are focused on providing innovative solutions to strengthen their position in the market. For instance, in July 2021, Nevro Corporation, a US-based medical device company, developed Senza (also known as "HFX"), a high spinal cord stimulation technology for the treatment of painful diabetic neuropathy (PDN), a condition that affects up to one-third of people with diabetes (PWDs) in the United States and causes loss of sensation and pain in the lower limbs. Senza® HFX iQTM is the next generation technology that uses artificial intelligence to optimise and maintain pain alleviation based on each patient's response. It was designed to take into consideration how different people experience pain and to help patients achieve and maintain long-term pain relief and an improved quality of life.The Senza HFX iQ system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, will be the first to use algorithms built specifically for treating chronic back and leg pain, such as severe diabetic neuropathy and non-surgical back pain.

In January 2022, Withings SA, a France-based consumer electronics company that designs, and manufactures a range of clinically validated smart health devices and associated apps, acquired Impeto Medical SAS for an undisclosed amount. This acquisition enables Withings to incorporate Impeto's technologies, including nerve tracking activity, into its products and services. Impeto Medical SAS is a France-based medical device company that manufactures tools for monitoring peripheral neuropathies to detect small fiber neuropathies in a variety of diseases and conditions.

The countries covered in the diabetic neuropathy market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The diabetic neuropathy market research report is one of a series of new reports from The Business Research Company that provides diabetic neuropathy market statistics, including diabetic neuropathy industry global market size, regional shares, competitors with a diabetic neuropathy market share, detailed diabetic neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic neuropathy industry. This diabetic neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Diabetic Neuropathy Market Characteristics

3. Diabetic Neuropathy Market Trends And Strategies

4. Diabetic Neuropathy Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Diabetic Neuropathy Market
• 4.2. Ukraine-Russia War Impact On Diabetic Neuropathy Market
• 4.3. Impact Of High Inflation On Diabetic Neuropathy Market

5. Diabetic Neuropathy Market Size And Growth

• 5.1. Global Diabetic Neuropathy Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Diabetic Neuropathy Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Diabetic Neuropathy Market Segmentation

• 6.1. Global Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy
• 6.2. Global Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Analgesics
• Anti-Depressants
• Anti-consulvants
• Other Drug Classes
• 6.3. Global Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Drug Treatment
• Radiotherapy
• Physiotherapy
• Other Treatments
• 6.4. Global Diabetic Neuropathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Online Distribution
• Offline Distribution
• 6.5. Global Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-users

7. Diabetic Neuropathy Market Regional And Country Analysis

• 7.1. Global Diabetic Neuropathy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Diabetic Neuropathy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Diabetic Neuropathy Market

• 8.1. Asia-Pacific Diabetic Neuropathy Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Diabetic Neuropathy Market

• 9.1. China Diabetic Neuropathy Market Overview
• 9.2. China Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Diabetic Neuropathy Market

• 10.1. India Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Diabetic Neuropathy Market

• 11.1. Japan Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Diabetic Neuropathy Market

• 12.1. Australia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Diabetic Neuropathy Market

• 13.1. Indonesia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Diabetic Neuropathy Market

• 14.1. South Korea Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Diabetic Neuropathy Market

• 15.1. Western Europe Diabetic Neuropathy Market Overview
• 15.2. Western Europe Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Diabetic Neuropathy Market

• 16.1. UK Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Diabetic Neuropathy Market

• 17.1. Germany Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Diabetic Neuropathy Market

• 18.1. France Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Diabetic Neuropathy Market

• 19.1. Eastern Europe Diabetic Neuropathy Market Overview
• 19.2. Eastern Europe Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Diabetic Neuropathy Market

• 20.1. Russia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Diabetic Neuropathy Market

• 21.1. North America Diabetic Neuropathy Market Overview
• 21.2. North America Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Diabetic Neuropathy Market

• 22.1. USA Diabetic Neuropathy Market Overview
• 22.2. USA Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Diabetic Neuropathy Market

• 23.1. South America Diabetic Neuropathy Market Overview
• 23.2. South America Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Diabetic Neuropathy Market

• 24.1. Brazil Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Diabetic Neuropathy Market

• 25.1. Middle East Diabetic Neuropathy Market Overview
• 25.2. Middle East Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Diabetic Neuropathy Market

• 26.1. Africa Diabetic Neuropathy Market Overview
• 26.2. Africa Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Diabetic Neuropathy Market, Segmentation By End-user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Diabetic Neuropathy Market Competitive Landscape And Company Profiles

• 27.1. Diabetic Neuropathy Market Competitive Landscape
• 27.2. Diabetic Neuropathy Market Company Profiles
  • 27.2.1. Pfizer Inc.
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Eli Lilly and Company
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. GSK PLC (GlaxoSmithKline PLC)
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. Daiichi Sankyo Company Limited
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Johnson & Johnson
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Diabetic Neuropathy Market

29. Diabetic Neuropathy Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer